BioPorto Dividend

Dividend criteria checks 0/6

BioPorto does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-DKK 0.13
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if BIOPOR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIOPOR's dividend payments have been increasing.

Dividend Yield vs Market

BioPorto Dividend Yield vs Market

How does BIOPOR dividend yield compare to the market?
Segment	Dividend Yield
Company (BIOPOR)	n/a
Market Bottom 25% (DK)	1.7%
Market Top 25% (DK)	5.7%
Industry Average (Biotechs)	1.8%
Analyst forecast in 3 Years (BIOPOR)	n/a

Notable Dividend: Unable to evaluate BIOPOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIOPOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate BIOPOR's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BIOPOR has not reported any payouts.

BioPorto Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

New minor risk - Shareholder dilution

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Price target decreased to kr.6.00

Consensus revenue estimates fall to kr.30.0m

Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019)

Bioporto A/S Provides Earnings Guidance for the Year 2021

BioPorto Provides Pipeline Update

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New 90-day high: kr.6.24

New 90-day high: kr.4.07

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Third quarter 2020 earnings released: kr.0.09 loss per share

Earnings beat expectations, revenue disappoints

BioPorto A/S, Annual General Meeting, Apr 29, 2021

BioPorto A/S has completed a Follow-on Equity Offering in the amount of DKK 106.632762 million.

BioPorto A/S Plans Initial Clinical Evaluation of Grad-Based Test for Rapid Detection of COVID-19 Virus